MBX Biosciences (MBX) Cash from Financing Activities (2023 - 2026)

MBX Biosciences has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $87.4 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $87.4 million, up 2185775.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $277.0 million (up 18.42% YoY), and the FY2025 annual result was $189.6 million, down 19.01% from the prior year.
• Cash from Financing Activities came in at $87.4 million for Q1 2026 at MBX Biosciences, up from $438000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $235.8 million in Q3 2024 to a low of -$1.8 million in Q2 2024.
• The 4-year median for Cash from Financing Activities is $310500.0 (2024), against an average of $51.1 million.
• Across the five-year window, Cash from Financing Activities plunged 794.74% in 2024 and surged 2185775.0% in 2026, its largest moves.
• MBX Biosciences' Cash from Financing Activities stood at $19000.0 in 2023, then slumped by 794.74% to -$132000.0 in 2024, then jumped by 431.82% to $438000.0 in 2025, then soared by 19862.33% to $87.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $87.4 million (Q1 2026), $438000.0 (Q4 2025), and $187.8 million (Q3 2025), per Business Quant data.